Accessible Search Form           Advanced Search

10. Research and Development Contracts


NHLBI Research and Development Contract Obligations:* Fiscal Years 2000–2010

NHLBI Research and Development Contract Obligations*:  Fiscal Years 1998-2008

Text-only With Data Points

* For detailed data on contract-supported clinical trials, see Chapter 11.

NHLBI Total Research and Development Contract Obligations: Fiscal Years 2000–2010

Dollars (Thousands)

 

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

FY 2005

FY 2006

FY 2007

FY 2008

FY 2009

FY 2010

Heart

$156,415

$184,491

$214,971

$258,647

$245,881

$219,796

$213,320

$260,205

$296,445

$321,223

$303,251

Lung

23,341

10,993

16,578

11,745

14,131

20,946

25,902

15,191

20,249

17,710

47,777

Blood

21,538

24,572

26,751

20,082

25,460

27,831

23,629

20,446

22,093

22,164

28,864

Total

$201,294A

$220,056B

$258,300C

$290,474D

$285,472E

$268,573F

$262,851G

$295,842H

$338,787I

$361,097J

$379,892K


A Includes Program Evaluation and IMPAC II Assessments of $17,944,000.
B Includes Program Evaluation and IMPAC II Assessments of $24,579,000.
C Includes Program Evaluation and IMPAC II Assessments of $35,827,000.
D Includes Program Evaluation and IMPAC II Assessments of $54,550,000.
E Includes Program Evaluation and IMPAC II Assessments of $57,545,722.
F Includes Program Evaluation and IMPAC II Assessments of $64,399,000.
G Includes Program Evaluation and IMPAC II Assessments of $67,795,000.
H Includes Program Evaluation and IMPAC II Assessments of $68,405,000.
I EIncludes Program Evaluation and IMPAC II Assessments of $77,487,000.
J Includes Program Evaluation and IMPAC II Assessments of $79,693,000.
K Includes Program Evaluation and IMPAC II Assessments of $83,834,100.
Note: From 2000 to 2006 the WHI was reported separately. In this table, it has been incorporated in the "Heart" line.

Back to Top

Major NHLBI Research and Development Contracts by Program

Total Obligations Prior to FY 2010

Total FY 2010 Obligations

Total Obligations to Date

Heart and Vascular Diseases

 

 

 

Atherosclerosis Risk in Communities (ARIC)

$149,712,440

$7,456,559

$157,168,999

Candidate Gene Association Resource (CARe)

22,420,575

2,351,820

24,772,395

Cardiovascular Health Study (CHS)

78,754,025

801,888

79,555,913

Clarification of Optimal Anticoagulation Through Genetics (COAG)*

6,167,062

6,167,062

Coronary Artery Risk Development in Young Adults (CARDIA)

98,363,316

775,143

99,138,459

DNA Resequencing and Genotyping

26,630,036

2,578,987

29,209,023

Framingham Heart Study (FHS)

113,632,876

2,076,405

115,709,281

Genetically Triggered Thoracic Aortic Aneurysms and Other Cardiovascular Conditions (GenTAC): National Registry

6,745,470

4,369,615

11,115,085

Global Health Centers of Excellence

13,399,780

999,984

14,399,764

Hispanic Community Health Study (HCHS)

51,239,547

228,993

51,468,540

Interagency Registry for Mechanical Circulatory Support (INTERMACS)

6,338,903

1,487,293

7,826,196

Jackson Heart Study (JHS)

38,406,573

87,684

38,494,257

Multi-Ethnic Study of Atherosclerosis (MESA)

101,275,569

1,703,851

102,979,420

NHLBI Gene Therapy Resource Program (GTRP)

19,127,735

2,625,737

21,753,472

NHLBI Programs of Excellence in Nanotechnology

65,777,271

65,777,271

Proteomics Initiative

157,606,085

16,912,672

174,518,757

Pumps for Kids, Infants, and Neonates (PumpKIN)

8,388,522

8,388,522

Studying Community Programs To Reduce Childhood Obesity

20,950,000

20,950,000

Systolic Blood Pressure Intervention Trial (SPRINT)

7,508,288

29,374,119

36,882,407

Lung Diseases

 

 

 

Lung Tissue Research Consortium

26,504,208

3,495,792

30,000,000

Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)

2,081,851

27,960,468

30,042,319

Blood Diseases and Resources

 

 

 

Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC)

599,990

599,990

Maintenance of NHLBI Biological Specimen Repository

17,664,473

1,668,235

19,332,708

NHLBI–CDC Registry and Surveillance System in Hemoglobinopathies (RuSH)

1,506,239

4,913,679

6,419,918

Production Assistance for Cellular Therapies (PACT)

10,826,333

10,826,333

Retrovirus Epidemiology Donor Study II (REDS-II)

43,591,343

9,425,551

53,016,894

Sickle Cell Disease Health-Related Quality of Life Questionnaire

5,172,976

564,672

5,737,648

Somatic Cell Therapy Processing Facilities

23,750,781

828,232

24,579,013

* Formerly known as Randomized Trial of Genotype-Guided Dosing of Warfarin Therapy.

Back to Top

Heart and Vascular Diseases Program

Atherosclerosis Risk in Communities (ARIC), Initiated in Fiscal Year 1985

The ARIC is a large, longitudinal study comprising a community surveillance component and a prospective cohort component to investigate the etiology of atherosclerosis and its clinical sequelae and variation in cardiovascular risk factors by race, gender, and location. The community surveillance component monitors trends in hospitalized myocardial infarction, fatal CHD, and heart failure (2005–2009) by race and gender in four U.S. communities. The cohort component investigates the etiology of CHD in 15,792 participants, aged 46–64 at baseline, who were selected from the same communities. The participants received an extensive examination upon entry into the study (1987–1989) that included gathering medical, social, and demographic data. Subsequent examinations occurred in 1990–1992, 1993–1995, and 1996–1998, followed by contact annually by telephone to assess the health status of the cohort. Beginning in 2011, the study will reexamine the cohort participants with a focus on heart failure—a major epidemic in the rapidly aging population in the United States. Three of the cohort components represent the racial mix of their community, and the fourth is exclusively black.

Obligations

Funding History:
Fiscal Year 2010—$7,456,559
Fiscal Years 1985–2009—$149,712,440
Total Funding to Date—$157,168,999

Current Active Organizations and Contract Numbers

  1. University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina —HC-55015
  2. Baylor College of Medicine
    Houston, Texas —HC-55016
  3. University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina —HC-55018
  4. University of Minnesota, Twin Cities
    Minneapolis, Minnesota —HC-55019
  5. Johns Hopkins University
    Baltimore, Maryland —HC-55020
  6. Mississippi Medical Center
    Jackson, Mississippi —HC-55021

Candidate Gene Association Resource (CARe), Initiated in Fiscal Year 2006

The CARe program is a shared genotype/phenotype resource for analyses of the association of genotypes with phenotypes relevant to the mission of the NHLBI. The resource comprises nine cohort studies funded by the NHLBI: ARIC, CHS, Cleveland Family Study, Cooperative Study of SCD, CARDIA, FHS, JHS, MESA, and the Sleep Heart Health Study. The database of genotypes and phenotypes (dbGaP) includes records for approximately 44,000 study participants with approximately 50,000 single nucleotide polymorphisms (SNPs) from more than 2,000 selected candidate genes. In addition, a genome-wide association study using a 1,000K SNP chip was conducted on approximately 8,500 black participants drawn from four CARe cohorts: ARIC, CARDIA, JHS, and MESA. Data from individual cohorts are available to approved investigators through dbGaP.

Obligations

Funding History:
Fiscal Year 2010—$2,351,820
Fiscal Years 2006–2009—$22,420,575
Total Funding to Date—$24,772,395

Current Active Organization and Contract Number

  1. The Broad Institute, Inc
    Cambridge, Massachusetts —268200900055C

Cardiovascular Health Study (CHS), Initiated in Fiscal Year 1988

The CHS is a population-based, longitudinal study of risk factors for development and progression of CHS and stroke in elderly adults, 17 percent of whom are from minority populations. Extensive data and samples have been collected from nearly 6,000 participants since 1989–1990. The current CHS: Transition Phase provides partial support for an infrastructure to enable continued access to study resources and expertise, scientific collaborations, and mentorship of early-career investigators.

Obligations

Funding History:
Fiscal Year 2010—$801,888
Fiscal Years 1988–2009—$78,754,025
Total Funding to Date—$79,555,913

Current Active Organization and Contract Number

  1. University of Washington
    Seattle, Washington —268200800007C

Clarification of Optimal Anticoagulation Through Genetics (COAG),* Initiated in 2008

See Chapter 11. Clinical Trials.

* Formerly known as Randomized Trial of Genotype-Guided Dosing of Warfarin Therapy.

Coronary Artery Risk Development in Young Adults (CARDIA), Initiated in Fiscal Year 1984

CARDIA is a long-term study that examines the evolution of CVD risk factors and early clinical events in a cohort of black and white adults, ages 18–30 years in 1985–1986. The study examines risk factors for heart and lung diseases by collecting information on body mass index, physical activity and lifestyle, genetics, serologic and metabolic components, inflammatory markers, and other subclinical measures of disease. Fifty percent of the participants are black.

Obligations

Funding History:
Fiscal Year 2010—$775,143
Fiscal Years 1984–2009—$98,363,316
Total Funding to Date—$99,138,459

Current Active Organizations and Contract Numbers

  1. Johns Hopkins University
    Baltimore, Maryland —HC-45241
  2. University of Alabama at Birmingham
    Birmingham, Alabama —HC-48047
  3. University of Minnesota, Twin Cities
    Minneapolis, Minnesota —HC-48048
  4. Northwestern University
    Chicago, Illinois —HC-48049
  5. Kaiser Permanente Division of Research
    Oakland, California —HC-48050
  6. University of Alabama at Birmingham
    Birmingham, Alabama —HC-95095

DNA Resequencing and Genotyping, Initiated in Fiscal Year 2004

The purpose of this program is to obtain rapid, reliable, and cost-efficient DNA sequencing and genotyping of candidate genomic regions potentially important in the disease pathways of heart, lung, and blood diseases and sleep disorders. This information will assist ongoing investigations of genetic components involved in the causes, variable outcome, and progression of the diseases and disorders.

Obligations

Funding History:
Fiscal Year 2010—$2,578,987
Fiscal Years 2004–2009—$26,630,036
Total Funding to Date—$29,209,023

Current Active Organizations and Contract Numbers

  1. University of Washington
    Seattle, Washington —HV-48194
  2. J. Craig Venter Institute, Inc.
    Rockville, Maryland —HV-48196

Framingham Heart Study (FHS)

The original Framingham Heart Study was designed as a longitudinal investigation of constitutional and environmental factors influencing the development of CVD in individuals free of these conditions at the outset. Of the original 5,209 subjects, about 200 members remain alive. In 1971, the Framingham Offspring Study was initiated to assess familial and genetic factors associated with CHD. More than 5,000 offspring (and their spouses) were included. A third-generation cohort consisting of approximately 4,000 grandchildren was added in 2002 to permit examination of numerous hypotheses about the genetic contribution to CVD and CVD risk factors. Additional goals include identifying new risk factors for cardiovascular, lung, and blood diseases and developing new imaging tests that can detect very early stages of coronary atherosclerosis in otherwise healthy adults. In 2009, the Omni Group 1 and Omni Group 2 cohorts were integrated into the NHLBI contract for the FHS. These two cohorts consist of minority residents of Framingham, Massachusetts (about 500 and 400 participants, respectively), and were previously identified, recruited, and examined through investigator-initiated grants. Their addition to the study reflects the growing diversity of the community.

Obligations

Funding History:
Fiscal Year 2010—$2,076,405
Fiscal Years 1983–2009—$113,632,876
Total Funding to Date—$115,709,281

Current Active Organization and Contract Number

  1. Boston University Medical Center
    Boston, Massachusetts —HC-25195

Genetically Triggered Thoracic Aortic Aneurysms and Other Cardiovascular Conditions (GenTAC): National Registry, Initiated in Fiscal Year 2006

The purpose of this program is to establish a national registry to enable investigators to determine the best medical practices to advance the clinical management of genetic thoracic aortic aneurysms and other cardiovascular complications associated with connective tissue diseases, such as Marfan, Loeys-Dietz, and Ehlers Danlos (vascular type) Syndromes.

Obligations

Funding History:
Fiscal Year 2010—$4,369,615
Fiscal Years 2006–2009—$6,745,470
Total Funding to Date—$11,115,085

Current Active Organization and Contract Number

  1. Research Triangle Institute
    Research Triangle Park, North Carolina —268201000048C

Global Health Centers of Excellence, Initiated in Fiscal Year 2009

The purpose of this program is to support a worldwide network of research and training centers to prevent and control chronic diseases, such as cardiovascular diseases, lung diseases, and diabetes. The NHLBI joined with Minneapolis-based UnitedHealth Group's Chronic Disease Initiative in establishing the UnitedHealth and NHLBI Collaborating Centers of Excellence network. Each center is led by a research institution in a low- or middle-income, developing country that is paired with at least one partner academic institution in a developed country to enhance research and training opportunities.

Obligations

Funding History
Fiscal Year 2010—$999,984
Fiscal Year 2009—$13,399,780
Total Funding to Date—$14,399,764

Current Active Organizations and Contract Numbers

  1. St. John's Research Institute
    Karnataka, India —HV-98215
  2. Public Health Foundation in India
    New Delhi, India —HV-98216
  3. The George Institutes in China
    Beijing, China —HV-98217
  4. Instituto de Nutrición de Centro América
    Guatemala City, Guatemala —HV-98218
  5. Institute for Clinical Effectiveness and Health Policy
    Buenos Aires, Argentina —HV-98219
  6. University of Cape Town
    Cape Town, South Africa —HV-98220
  7. Moi University School of Medicine
    Eldoret, Kenya —HV-98221
  8. International Center for Diarrhoeal Disease Branch
    Mohakhali, Bangladesh —HV-98222
  9. University of Peruana
    San Martin, Peru —HV-98223
  10. Westat
    Rockville, Maryland —HV-98224

Hispanic Community Health Study (HCHS), Initiated in Fiscal Year 2006

The purpose of this program is to determine the prevalence of and risk factors for cardiovascular and lung diseases in Hispanic populations and the role of cultural adaptation and disparities in development of these and other chronic diseases. The multicenter, 6.5-year epidemiology study comprises approximately 16,000 Hispanic/Latinos, aged 18–74 years, who self-identify as Mexican/Mexican American, Puerto Rican, Cuban, or Central or South American.

Obligations

Funding History:
Fiscal Year 2010—$228,993
Fiscal Years 2006–2009—$51,239,547
Total Funding to Date—$51,468,540

Current Active Organizations and Contract Numbers

  1. University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina —HC-65233
  2. University of Miami
    Miami, Florida —HC-65234
  3. Albert Einstein College of Medicine
    New York, New York —HC-65235
  4. Northwestern University
    Chicago, Illinois —HC-65236
  5. San Diego State University
    San Diego, California —HC-65237

Interagency Registry for Mechanical Circulatory Support (INTERMACS), Initiated in Fiscal Year 2005

The purpose of this program is to establish a data and clinical coordinating center to manage a registry of patients receiving an FDA-approved mechanical circulatory support device (MCSD) to treat heart failure. The registry will collect and analyze clinical and laboratory data and tissue samples from patients who receive MCSDs as destination therapy for end-stage heart failure at 90–100 participating hospitals.

Obligations

Funding History:
Fiscal Year 2010—$1,487,293
Fiscal Years 2005–2009—$6,338,903
Total Funding to Date—$7,826,196

Current Active Organization and Contract Number

  1. University of Alabama
    Birmingham, Alabama —HV-58198

Jackson Heart Study (JHS), Initiated in Fiscal Year 1998

The JHS is an epidemiologic study of CVD in blacks in Jackson, Mississippi, similar to established studies in Framingham, Massachusetts, and Honolulu, Hawaii. The goals of the study are to identify factors related to the development and progression of CVD and its risk factors and to assess roles of sociocultural factors (e.g., stress, racism, discrimination, coping strategies), hereditary factors, specific genetic variants, and gene–environment interactions in CVD among the black population. In addition, the JHS seeks to build research capabilities in minority institutions, address the critical shortage of minority investigators in epidemiology and prevention, and reduce barriers to dissemination and use of health information in a minority population.

Obligations

Funding History:
Fiscal Year 2010—$87,684
Fiscal Years 1998–2009—$38,406,573
Total Funding to Date—$38,494,257

Current Active Organizations and Contract Numbers

  1. Jackson State University
    Jackson, Mississippi —HC-95170
  2. Mississippi Medical Center
    Jackson, Mississippi —HC-95171
  3. Tougaloo College
    Tougaloo, Mississippi —HC-95172

Multi-Ethnic Study of Atherosclerosis (MESA), Initiated in Fiscal Year 1999

The purpose of this study is to investigate the prevalence, correlates, and progression of subclinical CVD (i.e., disease detected noninvasively before it has produced clinical signs and symptoms) in a population that is 38 percent white, 28 percent black, 22 percent Hispanic, and 12 percent Asian. A fifth examination began in 2010 and includes a measurement of cardiac function with MRI. Periodic monitoring of participants to identify recent hospitalizations and other clinical events will continue.

Obligations

Funding History:
Fiscal Year 2010—$1,703,851
Fiscal Years 1999–2009—$101,275,569
Total Funding to Date—$102,979,420

Current Active Organizations and Contract Numbers

  1. University of Washington
    Seattle, Washington —HC-95159
  2. University of California, Los Angeles
    Los Angeles, California —HC-95160
  3. Columbia University
    New York, New York —HC-95161
  4. Johns Hopkins University
    Baltimore, Maryland —HC-95162
  5. University of Minnesota, Twin Cities
    Minneapolis, Minnesota —HC-95163
  6. Northwestern University
    Chicago, Illinois —HC-95164
  7. Wake Forest University
    Winston-Salem, North Carolina —HC-95165
  8. University of Vermont
    Colchester, Vermont —HC-95166
  9. New England Medical Center
    Boston, Massachusetts —HC-95167
  10. Johns Hopkins University
    Baltimore, Maryland —HC-95168
  11. Harbor-UCLA Research and Education Institute
    Los Angeles, California —HC-95169

NHLBI Gene Therapy Resource Program (GTRP), Initiated in Fiscal Year 2007

The purpose of this program is to promote the translation of basic research into clinical trials. The program will support the production of safe and well-characterized vectors; conduct extensive toxicology and pharmacology studies on animals to determine vector dosing, related toxicity, and vector dissemination; and provide investigators with regulatory assistance to initiate a clinical trial. The GTRP also will support a maximum of two phase I/II gene transfer clinical trials per year that have successfully met all regulatory requirements and are ready to enroll patients within 12 months of application approval.

Obligations

Funding History:
Fiscal Year 2010—$2,625,737
Fiscal Years 2008–2009—$19,127,735
Total Funding to Date—$21,753,472

Current Active Organizations and Contract Numbers

  1. Social and Scientific Systems, Inc.
    Silver Spring, Maryland —HV-78200
  2. Lovelace Biomedical Research & Education Institute
    Albuquerque, New Mexico —HV-78201
  3. University of Pennsylvania
    Philadelphia, Pennsylvania —HV-78202
  4. Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania —HV-78203
  5. Indiana University
    Indianapolis, Indiana —HV-78204

NHLBI Programs of Excellence in Nanotechnology,* Initiated in Fiscal Year 2010

The purpose of this program is to establish multidisciplinary teams to develop nanotechnology and biomolecular engineering tools and methodologies for the diagnosis and treatment of heart, lung, and blood diseases and to translate these technologies toward clinical application. The program presents a unique opportunity for research collaboration and skills training by bringing bioengineering and nanotechnology solutions into medicine and vice versa.

Obligations

Funding History:
Fiscal Year 2010—$65,777,271
Total Funding to Date—$$65,777,271

Current Active Organizations and Contract Numbers

  1. Georgia Institute of Technology
    Atlanta, Georgia —268201000043C
  2. Massachusetts General Hospital
    Boston, Massachusetts —268201000044C
  3. Mount Sinai School of Medicine
    New York, New York —268201000045C
  4. Washington University
    St. Louis, Missouri —268201000046C

* NHLBI Programs of Excellence in Nanotechnology was a cooperative agreement from 2005 to 2009.

Proteomics Initiative, Initiated in Fiscal Year 2002

The purpose of this program is to establish highly interactive, multidisciplinary centers to enhance and develop innovative proteomic technologies directed to relevant biologic questions associated with heart, lung, blood, and sleep health and disease.

Obligations

Funding History:
Fiscal Year 2010—$16,912,672
Fiscal Years 2002–2009—$157,606,085
Total Funding to Date—$174,518,757

Current Active Organizations and Contract Numbers

  1. Medical University of South Carolina
    Charleston, South Carolina —HV-28181
  2. Boston University
    Boston, Massachusetts —268201000031C
  3. Johns Hopkins University
    Baltimore, Maryland —268201000032C
  4. Massachusetts General Hospital
    Boston, Massachusetts —268201000033C
  5. Stanford University
    Stanford, California —268201000034C
  6. University of California, Los Angeles
    Los Angeles, California —268201000035C
  7. University of Texas
    San Antonio, Texas —268201000036C
  8. University of Texas
    Galveston, Texas —268201000037C

Pumps for Kids, Infants, and Neonates (PumpKIN), Initiated in Fiscal Year 2010

The purpose of this program is to complete the preclinical testing of investigational MCSDs to be used in infants and young children with congenital and acquired CVD who experience cardiopulmonary failure and circulatory collapse.

Obligations

Funding History:
Fiscal Year 2010—$8,388,522
Total Funding to Date—$8,388,522

Current Active Organizations and Contract Numbers

  1. University of Pittsburgh
    Pittsburgh, Pennsylvania —268201000012C
  2. Jarvik Heart, Inc.
    New York, New York —268201000013C
  3. University of Maryland
    Baltimore, Maryland —268201000014C
  4. Ension, Inc.
    Pittsburgh, Pennsylvania —268201000015C

Studying Community Programs To Reduce Childhood Obesity, Initiated in Fiscal Year 2010

The purpose of this program is to establish a Research Coordinating Center to support a nationwide scientific study of communities to examine outcomes associated with characteristics of existing or new community programs and policies to reduce childhood obesity rates. The Center will partner with members of the National Collaborative on Childhood Obesity Research (NIH, Robert Wood Johnson Foundation, and CDC) to design and implement the research.

Obligations

Funding History:
Fiscal Year 2010—$20,950,000
Total Funding to Date—$20,950,000

Current Active Organization and Contract Number

  1. Batelle Memorial Institute
    Columbus, Ohio —HC-05265

Systolic Blood Pressure Intervention Trial (SPRINT), Initiated in 2009

See Chapter 11. Clinical Trials.

Lung Diseases Program

Lung Tissue Research Consortium, Initiated in Fiscal Year 2004

The purpose of this program is to establish a consortium for collecting lung tissues and preparing and distributing them for research. Scientists seek to improve management of lung diseases by increasing understanding of the pathogenetic mechanisms of lung diseases through molecular histopathological studies on tissues with and without disease. Primary emphases are on COPD and idiopathic pulmonary fibrosis.

Obligations

Funding History:
Fiscal Year 2010—$3,495,792
Fiscal Years 2004–2009—$26,504,208
Total Funding to Date—$30,000,000

Current Active Organizations and Contract Numbers

  1. Mayo Clinic College of Medicine
    Rochester, New York —HR-46158
  2. University of Colorado Health Science Center
    Denver, Colorado —HR-46159
  3. Mayo Clinic College of Medicine
    Rochester, New York —HR-46161
  4. University of Michigan
    Ann Arbor, Michigan —HR-46162
  5. University of Pittsburgh
    Pittsburgh, Pennsylvania —HR-46163
  6. Clinical Trials and Survey Corporation
    Baltimore, Maryland —HR-46164

Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS), Initiated in Fiscal Year 2009

See Chapter 11. Clinical Trials.

Blood Diseases and Resources Program

Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), Initiated in Fiscal Year 2010

The purpose of this program is to coordinate data and biospecimens from NHLBI-funded studies and make them available for use in other approved studies. The center will also create teaching datasets from NHLBI-funded studies for use in training future biostatisticians.

Obligations

Funding History:
Fiscal Year 2010—$599,990
Total Funding to Date—$599,990

Current Active Organization and Contract Number

  1. Information Management Services
    Rockville, Maryland —268200800012C

Maintenance of NHLBI Biological Specimen Repository, Initiated in Fiscal Year 1998

The purpose of this project is to establish an NHLBI Biological Specimen Repository for blood specimens from Institute-supported research. The Repository monitors storage, labeling, and testing of the specimens, as well as administers safe shipment of precise sample aliquots to approved investigators for future studies.

Obligations

Funding History:
Fiscal Year 2010—$1,668,235
Fiscal Years 1998–2009—$17,664,473
Total Funding to Date—$19,332,708

Current Active Organization and Contract Number

  1. SeraCare Life Sciences, Inc.
    Rockville, Maryland —HB-87144

NHLBI–CDC Registry and Surveillance System in Hemoglobinopathies (RuSH), Initiated in Fiscal Year 2009

The purpose of this program is to develop and implement a national data system and biospecimen repository that will provide data to describe the epidemiologic and clinical characteristics of people who have all genotypes of SCD, thalassemias, and other hemoglobinopathies. The system will be designed to collect, analyze, interpret, and disseminate data on the epidemiology, clinical correlates, health care use, and community resources of patients who have these conditions. It will support research, information dissemination, policy decisions, health care planning, and provider training at the local, state, and national levels.

Obligations

Funding History:
Fiscal Year 2010—$4,913, 679
Fiscal Year 2009—$1,506,239
Total Funding to Date—$6,419,918

Current Active Organization and Contract Number

  1. Centers for Disease Control and Prevention
    Atlanta, Georgia —HR-9045

Production Assistance for Cellular Therapies (PACT), Initiated in Fiscal Year 2010

The purpose of this program is to advance (a) cellular therapy research in the areas of regeneration of damaged or diseased tissues, organs, and biologic systems and (b) targeted treatments for serious diseases without effective therapies. The cell processing facilities will support translational research in innovative cell therapies to advance the field of cellular therapy and enable scientifically meritorious basic science research to reach the clinical trial stage.

Obligations

Funding History:
Fiscal Year 2010—$10,826,333
Total Funding to Date—$10,826,333

Current Active Organizations and Contract Numbers

  1. EMMES Corp.
    Rockville, Maryland —268201000006C
  2. Baylor College of Medicine
    Houston, Texas —268201000007C
  3. University of Minnesota
    Minneapolis, Minnesota —268201000008C
  4. Immune Disease Institutes
    Boston, Massachusetts —268201000009C
  5. University of Wisconsin
    Madison, Wisconsin —268201000010C
  6. Beckman Research Institutes
    Duarte, California —268201000011C

Retrovirus Epidemiology Donor Study-II (REDS-II), Initiated in Fiscal Year 2005

The purpose of this program is to conduct epidemiologic, laboratory, and survey research on volunteer blood donors within the United States to ensure the safety and availability of the blood supply. The study seeks to assess the prevalence and incidence of existing and newly discovered infectious agents that pose a threat to blood safety; evaluate characteristics and behaviors of voluntary blood donors; determine the causes of adverse transfusion reactions of unknown etiology; assess new and existing blood donor screening methodologies; assess the impact of new blood bank technologies on blood safety and availability; and evaluate the donation process for ways to improve the adequacy of the blood supply.

An international component was added to conduct epidemiologic, laboratory, and survey research on blood donors in China and Brazil, two countries seriously affected by the AIDS epidemic, to ensure the availability and safety of blood for transfusion.

Obligations

Funding History:
Fiscal Year 2010—$9,425,551
Fiscal Years 2005–2009—$43,591,343
Total Funding to Date—$53,016,894

Current Active Organizations and Contract Numbers

  1. Blood Center of Southeastern Wisconsin
    Milwaukee, Wisconsin —HB-47168
  2. American Red Cross Blood Service, New England
    Farmington, Connecticut —HB-47169
  3. Emory University
    Atlanta, Georgia —HB-47170
  4. University of Cincinnati
    Cincinnati, Ohio —HB-47171
  5. Institute for Transfusion Medicine
    Pittsburgh, Pennsylvania —HB-47172
  6. University of California, San Francisco
    San Francisco, California —HB-47174
  7. Westat, Inc.
    Rockville, Maryland —HB-47175
  8. Blood System Research, Inc.
    San Francisco, California —HB-57181

Sickle Cell Disease Health-Related Quality of Life Questionnaire, Initiated in 2005

The purpose of this project is to develop a psychometrically sound and clinically relevant health-related quality of life instrument and related materials for use in sickle cell clinical trials and outcomes research.

Obligations

Funding History:
Fiscal Year 2010—$564,672
Fiscal Years 2005–2009—$5,172,976
Total Funding to Date—$5,737,648

Current Active Organization and Contract Number

  1. Blood Center of Southeastern Wisconsin
    Milwaukee, Wisconsin —HL-54264

Somatic Cell Therapy Processing Facilities, Initiated in Fiscal Year 2003

The purpose of this project is to develop novel somatic cellular therapies in areas ranging from basic science through animal studies to proof-of-principle and eventually human trials for heart, lung, and blood diseases and sleep disorders. The goal is to provide rapid, safe translation of basic research ideas into clinical practice.

Obligations

Funding History:
Fiscal Year 2010—$828,232
Fiscal Years 2003–2009—$23,750,781
Total Funding to Date—$24,579,013

Current Active Organization and Contract Number

  1. University of Minnesota, Twin Cities
    Minneapolis, Minnesota —HB-37164

Back to Top

« Back

Next »

Fact Book Table of Contents

Twitter iconTwitterimage of external icon Facebook iconFacebookimage of external icon YouTube iconYouTubeimage of external icon Google+ iconGoogle+image of external icon